Is the price fair?
What LLY's price assumes
Lilly (Eli) trades at 39.9× earnings against 27.4× for the median Drug Manufacturers - General name, more expensive than its own group.
39.9
Trailing P/E · Drug Manufacturers - General median 27.4 · 1.46× the median: the market pays up for this one
- Price / sales
- 11.4
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.9%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- +19%
Growth the price implies · The price pays for +19% free cash flow growth a year for a decade; the business has delivered +70% a year over the last three.
Details›
- Price / book2026-Q1
- 26.4
- EV / sales2026-Q1
- 11.9
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - General median P/E16 names
- 27.4
- Free cash flow, trailing twelve months
- $18.2B
- Market capitalisation
- $979.6B
- 3-year revenue growth
- +39%
- 3-year free cash flow growth
- +70%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $847.80 |
| Its own P/E history, median | $1,248.11 |
| Its own P/E history, upper quartile | $1,992.22 |
| 52-week range | $621.26 – $1,279.81 |
| Today | $1,189.68 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #1 of 16 by Smart Score